Trial design
Tg/LT4
THYROID NODULE
Prospective randomized open phase III non-inferiority trial in patients with cT1bT2N0 [

Before surgery, the patients will first be pre-registered (included) to check that the thyroid nodule is classified cT1bT2N0 and the FNAB cytology is classified type 5 or 6 according to the Bethesda classification [Surgery must be performed within 4 months of inclusion.For patients with For patients with All patients will have Tg/LT4 measured 8 +/−2 weeks postoperatively, All patients will receive, 2–4 months postoperatively, 30 mCi (1.1 GBq) Patients will be evaluated at 8 +/−2 months post-iodine (8–14 months postoperatively or “1 year”) then yearly with neck ultrasound, unstimulated ultrasensitive thyroglobulin (usTg/LT4), and anti-Tg antibodies.